A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 2,075,000 shares of JANX stock, worth $116 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
2,075,000
Previous 2,327,896 10.86%
Holding current value
$116 Million
Previous $97.5 Million 3.33%
% of portfolio
0.17%
Previous 0.19%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$35.29 - $50.26 $8.92 Million - $12.7 Million
-252,896 Reduced 10.86%
2,075,000 $94.3 Million
Q2 2024

Aug 14, 2024

SELL
$35.12 - $64.78 $15.7 Million - $29 Million
-447,776 Reduced 16.13%
2,327,896 $97.5 Million
Q1 2024

May 15, 2024

BUY
$7.93 - $49.75 $11.3 Million - $70.7 Million
1,420,197 Added 104.77%
2,775,672 $105 Million
Q4 2023

Feb 14, 2024

BUY
$5.85 - $11.7 $1.2 Million - $2.4 Million
205,475 Added 17.87%
1,355,475 $14.5 Million
Q3 2023

Nov 14, 2023

BUY
$9.56 - $14.0 $2.39 Million - $3.5 Million
250,000 Added 27.78%
1,150,000 $11.6 Million
Q1 2023

May 15, 2023

BUY
$11.25 - $22.21 $2.24 Million - $4.42 Million
198,934 Added 28.38%
900,000 $10.9 Million
Q4 2022

Feb 14, 2023

BUY
$11.1 - $18.26 $3.34 Million - $5.5 Million
301,066 Added 75.27%
701,066 $9.23 Million
Q3 2021

Nov 15, 2021

SELL
$20.7 - $34.69 $1.04 Million - $1.73 Million
-50,000 Reduced 11.11%
400,000 $8.65 Million
Q2 2021

Aug 16, 2021

BUY
$18.58 - $25.37 $8.36 Million - $11.4 Million
450,000 New
450,000 $11.2 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.34B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.